Apr 6, 2021, 1:45 PM
(From CNN) Clinical trial results of Pfizer's Covid-19 vaccine showed its efficacy is 100% and it is well tolerated in youths ages 12 to 15, the company said Wednesday. During the clinical trial, 18 people who were in the placebo group developed COVID-19, while none of the people in the vaccinated group did. Blood tests showed a strong immune system response one month after participants received the second vaccine dose, according to a summary of test data. Pfizer and its vaccine partner BioNTech plan to submit the data to the US Food and Drug Administration as soon as possible for expanded emergency use authorization of the two-dose vaccine.
"The bottom line is that by the fall I think there's a good possibility we'll be vaccinating teenagers, 12 and up, and for middle schools, junior high schools, high schools, it's really good news in the United States for both teachers and staff," said Dr. Peter Hotez, co-director of the Center for Vaccine Development at Texas Children's Hospital.
Listen to the latest episode of the Net Assets podcast.
